J Womens Health:低剂量阿司匹林可以降低女性糖尿病患者乳腺癌风险

2017-06-09 sunshine2015 来宝网

近日,《女性健康》杂志上刊登了一篇标题为《低剂量的阿司匹林可以减少糖尿病女性患乳腺癌风险》的文章,这是一份来自台湾中山医学院的研究人员进行的一次回顾性研究结果报告。

近日,《女性健康》杂志上刊登了一篇标题为《低剂量的阿司匹林可以减少糖尿病女性患乳腺癌风险》的文章,这是一份来自台湾中山医学院的研究人员进行的一次回顾性研究结果报告。



在此次试验中,研究人员对比了14.9万例女性糖尿病患者的病例,她们的糖尿病患病时间都超过14年,研究人员对比分析了这些参与者的用药情况,在各类药物对比之后,研究人员得出结论。他们发现,长期服用低剂量阿司匹林可以将女性糖尿病患者患乳腺癌的风险降低18%。

那么,低剂量阿司匹林的使用定义是什么呢?研究人员建议每天摄入75 - 165毫克阿司匹林。研究人员在文章中指出,如果糖尿病患者服用低剂量阿司匹林的时间正好是他们回顾研究的这14年,那么高累积剂量的阿司匹林久可以将患乳腺癌的风险降低了47%,相反,中低累积剂量起不到任何作用。

另外,来自弗吉尼亚联邦大学研究所,女性健康学院的研究人员也表示:“乳腺癌是2型糖尿病女性患者的其中一个并发症,长期低剂量的阿司匹林可以有效减少这一风险,除此之外,这些研究结果还表明,低剂量的阿司匹林不仅可以降低女性患乳腺癌的风险,还可以有效的预防血管疾病。”

原始出处:

Yang Yi-Sun, Kornelius Edy, et al. Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan Journal of Women's Health. May 2017, ahead of print. https://doi.org/10.1089/jwh.2016.6040

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061628, encodeId=0d9720616288a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 09 04:52:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861101, encodeId=4947186110103, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 24 11:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007453, encodeId=ca96200e45329, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Dec 15 15:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770275, encodeId=c9d21e702755f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Nov 29 13:52:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474200, encodeId=9d0914e420077, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480445, encodeId=deff1480445c7, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621615, encodeId=eb331621615f4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208637, encodeId=354320863e47, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Jun 09 16:02:48 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2018-03-09 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061628, encodeId=0d9720616288a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 09 04:52:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861101, encodeId=4947186110103, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 24 11:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007453, encodeId=ca96200e45329, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Dec 15 15:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770275, encodeId=c9d21e702755f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Nov 29 13:52:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474200, encodeId=9d0914e420077, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480445, encodeId=deff1480445c7, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621615, encodeId=eb331621615f4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208637, encodeId=354320863e47, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Jun 09 16:02:48 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-09-24 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061628, encodeId=0d9720616288a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 09 04:52:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861101, encodeId=4947186110103, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 24 11:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007453, encodeId=ca96200e45329, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Dec 15 15:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770275, encodeId=c9d21e702755f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Nov 29 13:52:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474200, encodeId=9d0914e420077, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480445, encodeId=deff1480445c7, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621615, encodeId=eb331621615f4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208637, encodeId=354320863e47, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Jun 09 16:02:48 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061628, encodeId=0d9720616288a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 09 04:52:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861101, encodeId=4947186110103, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 24 11:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007453, encodeId=ca96200e45329, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Dec 15 15:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770275, encodeId=c9d21e702755f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Nov 29 13:52:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474200, encodeId=9d0914e420077, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480445, encodeId=deff1480445c7, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621615, encodeId=eb331621615f4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208637, encodeId=354320863e47, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Jun 09 16:02:48 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061628, encodeId=0d9720616288a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 09 04:52:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861101, encodeId=4947186110103, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 24 11:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007453, encodeId=ca96200e45329, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Dec 15 15:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770275, encodeId=c9d21e702755f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Nov 29 13:52:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474200, encodeId=9d0914e420077, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480445, encodeId=deff1480445c7, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621615, encodeId=eb331621615f4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208637, encodeId=354320863e47, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Jun 09 16:02:48 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2061628, encodeId=0d9720616288a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 09 04:52:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861101, encodeId=4947186110103, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 24 11:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007453, encodeId=ca96200e45329, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Dec 15 15:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770275, encodeId=c9d21e702755f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Nov 29 13:52:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474200, encodeId=9d0914e420077, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480445, encodeId=deff1480445c7, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621615, encodeId=eb331621615f4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208637, encodeId=354320863e47, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Jun 09 16:02:48 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2061628, encodeId=0d9720616288a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 09 04:52:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861101, encodeId=4947186110103, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 24 11:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007453, encodeId=ca96200e45329, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Dec 15 15:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770275, encodeId=c9d21e702755f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Nov 29 13:52:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474200, encodeId=9d0914e420077, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480445, encodeId=deff1480445c7, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621615, encodeId=eb331621615f4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208637, encodeId=354320863e47, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Jun 09 16:02:48 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2061628, encodeId=0d9720616288a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 09 04:52:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861101, encodeId=4947186110103, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 24 11:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007453, encodeId=ca96200e45329, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Dec 15 15:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770275, encodeId=c9d21e702755f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Nov 29 13:52:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474200, encodeId=9d0914e420077, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480445, encodeId=deff1480445c7, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621615, encodeId=eb331621615f4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Jun 11 03:52:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208637, encodeId=354320863e47, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Jun 09 16:02:48 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-09 明天会更好!

    学习过了,很好值得分享!

    0

相关资讯

13万人大数据:长期服用阿司匹林减少癌症死亡

长期服用阿司匹林能降低几种主要癌症死亡率(图片来源:《Time》)我们都听过规律服用阿司匹林可以降低心脏病和中风的风险,现在这一益处又扩展到了降低某些癌症的死亡率。在近期举行的美国癌症研究协会(AACR)年会上,来自著名医院麻省总医院(Massachusetts General Hospital)和哈佛医学院(Harvard Medical School)的一项研究发现,规律服用阿司匹林可

Heart Rhythm 2017:长期服用阿司匹林并不能降低中风风险

位于盐湖城的山间医学中心心脏研究所的研究人员的一项新研究发现,长期使用阿斯匹林来防止中风患者的中风可能并不像以前认为的那样有效。

神药阿司匹林:退烧、镇痛、预防心脏病,还可能阻止癌症扩散

撰文:薇薇安·卡列尔(Viviane Callier)翻译:贾明月如果世上真的存在神药,那一定是阿司匹林。这种最初从柳树皮中提取出的药物逐渐扬名立万,成为家庭药箱的中流砥柱。在好几辈人的手中,它成功地治疗了多种疾病,比如关节炎和发烧。有时人们会把它当作预防性的药物,防止卒中和心脏病发作,或者尝试用它预防特殊类型的癌症。这种药实在太受欢迎了,在全世界范围内,每年都会售出大约1200亿片的阿司匹林

J Thromb Haemost:CABG后患者服用阿司匹林是每日一次还是每日两次?

由此可见,每日多次剂量ASA比每日一次ASA每次81mg或325mg在CABG后抑制血清TXB2形成方面更有效。每日两次的治疗方案需要在临床结局的研究中进行验证。

Neurology:氯吡格雷-阿司匹林治疗小卒中或TIA的风险和获益

2017年5月,发表在《Neurology》上的CHANCE试验的分析,考察了氯吡格雷-阿司匹林治疗小卒中或TIA的风险和获益。目的:考察氯吡格雷联合阿司匹林治疗缺血性小卒中或TIA的短期风险和获益。方法:从急性非致残性脑血管事件高风险患者使用氯吡格雷(Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular

“神药”阿司匹林的16个副作用,你了解吗?

阿司匹林在一般治疗剂量时,不良反应较少;大剂量(如抗风湿治疗)或长期服用时,则有一定的不良反应。